Quiz 2 Flashcards
(116 cards)
Herpes Zoster Epidemiology
-Commonly called shingles
-reactivation of latent varicella zoster virus ‘
-Incidence and severity increase with age
-Risk increased by immunosuppression
Herpes Zoster complications
Post-therapeutic neuralgia - persistent pain after skin lesions healed
May limit daily activities and decrease quality of life
Zoster vaccines
Live attenuated zoster vaccine (ZVL)
-Licensed for individual > 50 years
-No longer marketed in the US cause not as effective
-Zostavax
Recombinant zoster vaccine (RZV)
-contains recombinant glycoprotein E and adjuvant
-two dose series 0 and 2-6 months
-Shingrix
RZV vaccine complications
-About 91% effective in prevention of zoster
-Injection site reactions are common (78%)
Immunocompromised
70% in auHSCT and 87% in hematologic malignancy
ACIP recommendations Herpes Zoster
Recommended for all adults >50 years
-Recombinant zoster vaccine two doses 2-6 months apart
All immunosuppressed individuals aged 19 years and older
-0 and 2 months
Respiratory Syncytial Virus (RSV) epidemiology
-Common seasonal respiratory virus
-Very contagious
-Well known to cause hospitalization with bronchiolitis and wheezing in infants
-Considerable burden of illness in adults
*65 and older
*Chronic illness, heart, hematologic, neurologic, diabetes, kidney, liver, immunocompromise, others
Respiratory Syncytial Virus (RSV)
Infants
-Acute respiratory illness symptoms
**runny nose
**decreased oral intake
Adults
-Acute respiratory illness
**Rhinorrhea
**Pharyngitis
**Cough
**Headache
**Fatigue
**Fever
RSV vaccines
Pfizer bivalent RSVpreF (Abrysvo)
GSK adjuvanted RSVpreF3
(Abrexvy)
-single dose
Both demonstrated efficacy against lower respiratory tract RSV infection over at least 2 seasons in individuals aged 60+ years
ACIP:
1. Single dose all adults > 75 years old
2. Adults aged 60-74 years with certain chronic medical conditions or other factors that increase risk of severe RSV –> single dose
Risk factors RSV
-CV disease
-Lung disease
-End stage renal disease
-Diabetes with end-organ damage
-Severe obesity
-Liver disorders
-Neurologic or neuromuscular disorders
-Hematologic disorders
-Moderate to severe immunocompromise
-Frailty
-Long term care resident
-Chronic med conditions
Adverse reactions RSV
Injection site reactions
-Arthralgia, myalgia, fatigue, headache
-No difference in incidence of serious adverse effects compared to placebo
Guillain-Barre syndrome
RSV for pregnant person
RSV vaccine during pregnancy weeks 32-36 gestation (passive immunity for infant)
-Injection site and systemic adverse reactions resolved in 2-3 days
-No risk to to preterm birth
Nirsevimab for infants
-Long acting monoclonal antibody with efficacy in the prevention of lower respiratory tract RSV infection
-Administer just prior or during RSV season - October to March
-Eligible infants < 8 months born prior to or during RSV season
-Eligible children aged 8-19 months at increased prior to or during second RSV season
Covid-19 pathology
-Respiratory symptoms by SARS CoV2 virus
-Fevers or chills
-Cough
-Shortness of breath
-Fatigue
-Myalgia
-Headache
-New loss of taste or small
-Sore throat
-Congestion
-Nausea, vomiting, diarrhea
COVID-19 epidemiology
Risk is substantially lower compared to early in pandemic
COVID-19 vaccine
mRNA vaccine
Target virus in same lineage
Moderna/Pfizer > 6 months
Novavax > 12 years
ACIP recommendation
All individuals aged 6 months or older
*Updated in Fall 2024 to improve response to currently circulating variants
Precaution
A condition in a vaccine recipient which may result in a problem if a vaccine is administered or a condition which could compromise the ability of a vaccine to induce immunity
Pregnancy
Benefit and risk assessment for vaccines
*risk cannot be ruled out by benefit may justify the risk
Routine prenatal care includes immunization history
Refer for prenatal care
*avoid live vaccines
*defer HPV immunization till after pregnancy
*Tdap in late 2nd or 3rd trimester
Influenza vaccine in pregnancy
Pregnant individuals at high risk for morbidity associated with influenza infection
4 fold increased risk of hospitalization and death
*vaccine recommended for pregnant individuals
RSV vaccine for pregnant individuals
RSV vaccine (Abrysvo) during pregnancy weeks 32-36
*passive immunity for infant
*Don’t use adjuvanted RSV
*Only vaccinate when gestation lines up seasonally (September to January)
Post partum (post birth) immunization
Rubella and/or varicella vaccines for seronegative
Tdap at hospital discharge if unimmunized
Influenza vaccine in season and unimmunized
Is lactation a contraindication?
No for mother and infant immunization
Immunosuppression
Two pronged risk
*risk of vaccine induced mortality or morbidity
*risk of poor host response to vaccine
Various diseases
*HIV, cancer, generalized malignancy
Various meds
*alkylating agents, antimetabolites, radiation
*corticosteroids (>20 mg/day) or prednisone (> 2 mg/kg/day) for more than 2 weeks
-Biologics, transplant meds
Immunosuppressed recommendations
-No lives vaccines
-OPV and small pox vaccines should not be administered to a household contact (risk of developing live disease)
-LAIV not administered to contacts of those requiring protective environment
-Can do the pneumococcal vaccine, or zoster vaccine series
Asplenia
Increased risk for fulminant bacteremia
Give meningococcal and pneumococcal vaccines if under 2
Hib vaccine
*If the splenectomy is elective (meaning you have time) immunize two weeks prior to surgery
*Annual influenza vaccination recommended